GleamWall
中文EN

KYMR Kymera Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1815442 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY133.8%
TTM net income YoY-18.4%
TTM EPS YoY-1.1%
Revenue 3-yr CAGR29.7%
Net income 3-yr CAGR—

Margins

Gross margin0.0%
Operating margin-396.0%
Net margin-341.8%
FCF margin-282.6%
EBITDA margin-388.9%

Returns

ROE-27.3%
ROA-24.4%
ROIC (approx.)-30.8%
Asset turnover0.07x

Leverage & solvency

Liabilities / assets8.6%
Debt / equity0.00x
Current ratio11.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.82x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$39.21M$47.07M
Cost of revenue$39.21M$47.07M
Gross profit$0$0
R&D expense$316.57M$240.25M
SG&A expense$68.19M$63.53M
Operating income-$349.40M-$261.63M
Pretax income-$311.35M—
Income tax$0—
Net income-$311.35M-$223.86M
EBITDA-$341.09M-$254.26M
EPS (basic)-3.69-2.98
EPS (diluted)-3.69-2.98
Weighted avg. shares (diluted)84.49M75.04M
Balance sheet
Cash & equivalents$357.01M$120.26M
Short-term investments$491.26M$368.49M
Receivables$0$0
Current assets$871.21M$510.27M
PP&E, net$43.17M$50.46M
Total assets$1.74B$978.03M
Current liabilities$83.21M$67.77M
Total liabilities$163.15M$142.42M
Shareholders' equity$1.58B$835.62M
Shares outstanding81.32M64.89M
Cash flow statement
Operating cash flow-$232.89M-$194.50M
Capital expenditure$1.45M$12.84M
Free cash flow-$234.34M-$207.34M
Investing cash flow-$521.06M-$404.08M
Financing cash flow$990.71M$608.85M
Depreciation & amortization$8.31M$7.37M
Stock-based compensation$59.90M$55.01M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.